Dear ,

In the current issue of the OncoWuXi Newsletter, we share with you the update on our service and newly established capabilities.

OncoWuXi Newsletter will continue to keep you up to date with our recent progress in cancer research. As a part of the WuXi AppTec Research Service Division (RSD), our top-notch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases, and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.
Translational Oncology
Entrectinib-induced Resistant KM-12 Colorectal Cancer CDX Model and CO-04-0284 Colorectal Cancer PDX Model

Tumor Metastasis Mouse Models

  • Enable the research of potential therapies against tumor metastasis
  • Multiple tumor metastasis mouse models including orthotopic-based, experimental, and spontaneous metastasis models

Targeted Oncology
TRK-related In Vivo Models

(1)  TRK-related CDX models
  • KM-12 colorectal cancer CDX model carrying TPM3-NTRK1 fusion, tested with LOXO-101
  • Genetically engineered Ba/F3 models carrying NTRK fusion, tested with LOXO-101 and Entrectinib both in vitro and in vivo

(2)  TRK-related PDX model
  • CO-04-0284 colorectal cancer PDX model carrying TPM3-NTRK1 fusion, tested with Entrectinib

BTK-related In Vivo Models

(1)  BTK-related CDX models
  • REC-1 and Mino mantle cell lymphoma CDX models, DoHH2 B cell lymphoma CDX model, SU-DHL-6 and SU-DHL-10 DLBCL CDX models, tested with Ibrutinib

(2)  BTK-related PDX models
  • Ten lymphoma PDX models are available, tested with Ibrutinib

We sincerely appreciate your interest, time and support, and would like to hear your feedback so that we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns.
Best regards,
WuXi AppTec OncoWuXi Team